Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 22 points (-0.2%) at 14,556 as of Monday, April 1, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 762 issues advancing vs. 2,184 declining with 121 unchanged. The Health Care sector currently sits down 1.1% versus the S&P 500, which is down 0.6%. On the negative front, top decliners within the sector include Vertex Pharmaceuticals ( VRTX), down 1.6%, Thermo Fisher Scientific ( TMO), down 1.3%, Gilead ( GILD), down 1.1%, Aetna ( AET), down 1.2% and Zimmer Holdings ( ZMH), down 0.9%. A company within the sector that increased today was Celgene Corporation ( CELG), up 1.0%. TheStreet Ratings group would like to highlight 5 stocks pushing the sector lower today: 5. Cigna ( CI) is one of the companies pushing the Health Care sector lower today. As of noon trading, Cigna is down $0.46 (-0.7%) to $61.91 on light volume Thus far, 725,756 shares of Cigna exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $61.88-$62.58 after having opened the day at $62.34 as compared to the previous trading day's close of $62.37. Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. Cigna has a market cap of $17.8 billion and is part of the health services industry. The company has a P/E ratio of 11.1, below the S&P 500 P/E ratio of 17.7. Shares are up 16.7% year to date as of the close of trading on Thursday. Currently there are 9 analysts that rate Cigna a buy, no analysts rate it a sell, and 5 rate it a hold. TheStreet Ratings rates Cigna as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Cigna Ratings Report now. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.